Experimental cell therapy targets tough blood cancers
NCT ID NCT07345780
Summary
This early-stage study is testing a personalized cell therapy called CAR-T for adults with certain hard-to-treat blood cancers that have returned or not responded to standard treatments. Researchers will check if the treatment is safe, how it behaves in the body, and if it shows signs of helping control the cancer. The study plans to enroll about 20-28 participants who have cancers that test positive for a marker called CD7.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD7-POSITIVE HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.